Abstract
For advanced carcinomas of the esophagus multimodal therapies consisting of neoadjuvant treatment with chemo- and/or radiation followed by surgical resection are the standard of care in western countries. Still unknown remains the question if clinical full responders to neoadjuvant treatment should receive an esophagectomy with all its perioperative risks as they could be pathological full responders potentially without further oncologic benefit. In this article we discuss the possible benefits and disadvantages of an organ sparing approach in comparison of the standard of care for patients with esophageal cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Foregut: The Journal of the American Foregut Society
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
